Adverum Biotechnologies(ADVM)
搜索文档
Adverum Biotechnologies(ADVM) - 2019 Q4 - Annual Report
2020-03-13 04:40
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | --- | |---------------------------------------------------------------------------------------------------|--------------------------------------------------| | | | | For the transition period from t ...
Adverum Biotechnologies(ADVM) - 2019 Q3 - Earnings Call Transcript
2019-11-10 20:55
Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Q3 2019 Earnings Conference Call November 7, 2019 4:30 PM ET Company Participants Myesha Lacy - Vice President of Investor Relations & Corporate Communications Leone Patterson - Chief Executive Officer Aaron Osborne - Chief Medical Officer Conference Call Participants Tyler Van Buren - Piper Jaffray Emma Nealon - Cantor Fitzgerald Phil Nadeau - Cowen & Company Joon Lee - SunTrust Patrick Dolezal - LifeSci Capital Myesha Lacy Thank you, and welcome, everyone. Today ...
Adverum Biotechnologies(ADVM) - 2019 Q3 - Quarterly Report
2019-11-08 05:24
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | --- | --- | --- | |---------------------------------------------------------------------------------------|-----------------------------------------------------------------|------ ...
Adverum Biotechnologies(ADVM) - 2019 Q2 - Earnings Call Transcript
2019-08-09 13:07
Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Q2 2019 Earnings Conference Call August 8, 2019 4:30 PM ET Company Participants Myesha Lacy - Vice President of Investor Relations & Corporate Communications Leone Patterson - Chief Executive Officer Aaron Osborne - Chief Medical Officer Thomas Leung - Chief Financial Officer Conference Call Participants Tyler Van Buren - Piper Jaffray Phil Nadeau - Cowen and Company Joon Lee - SunTrust Robinson Dane Leone - Raymond James Operator Good afternoon and welcome to the ...
Adverum Biotechnologies(ADVM) - 2019 Q2 - Quarterly Report
2019-08-09 04:07
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36579 Adverum Biotechnologies, Inc. (Exact name of registrant as specified in its charter) Delaware 20-5258327 (State or other jur ...
Adverum Biotechnologies(ADVM) - 2019 Q1 - Quarterly Report
2019-05-09 04:13
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36579 Adverum Biotechnologies, Inc. (Exact name of registrant as specified in its charter) Delaware 20-5258327 (State or other ju ...
Adverum Biotechnologies(ADVM) - 2018 Q4 - Annual Report
2019-03-07 06:31
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | --- | |---------------------------------------------------------------------------------------------------|--------------------------------------------------| | | | | For the transition period from t ...